CAS NO: | 110267-81-7 |
包装: | 1mg |
市场价: | 3200元 |
生物活性 | Amrubicin (SM-5887) is a DNAtopoisomeraseIIinhibitor, used for the research ofcancer. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Amrubicin (SM-5887) is a DNA topoisomerase II inhibitor. Amrubicin (SM-5887) (2.5 μg/mL) shows radio-enhancement effects on human lung adenocarcinoma A549 cells[1]. Amrubicin supresses the LX-1, A549, A431, and BT-474 cell lines, with IC50s of 1.1 ± 0.2, 2.4 ± 0.8, 0.61 ± 0.10 and 3.0 ± 0.3 μg/mL, respectively[2]. Amrubicin inhibits the cell cycle profile of U937 cells with an IC50of 5.6 μM. Amrubicin (SM-5887) (20 μM) also induces apoptosis in U937 cells, activates caspase-3/7 and reduces the mitochondrial membrane potential (Δψm)[3]. | ||||||||||||||||
体内研究 (In Vivo) | Amrubicin (SM-5887) (25 mg/kg, i.v.) exhibits significant antitumor activities against both SCLC tumors, Lu-24 and Lu-134, with T/C-values (comparing the mean tumor growth rates of the treated group with those of the control group for each day that the tumors are measured) at day 14 of 17% and 9%, respectively. Amrubicin (SM-5887) (25 mg/kg, i.v.) in combination with cisplatin and irinotecan significantly inhibits the growth of tumors compared to amrubicin alone in mice bearing LX-1 tumor cells. Amrubicin (SM-5887) alone or combined with tegafur and uracil also suppresses tumor growth in human cancer xenograft models[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 483.47 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C25H25NO9 | ||||||||||||||||
CAS 号 | 110267-81-7 | ||||||||||||||||
中文名称 | 氨柔比星 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 30 mg/mL(62.05 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |